Tags

Type your tag names separated by a space and hit enter

In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Chemotherapy. 2001 Jul-Aug; 47(4):243-9.C

Abstract

The in vitro activities of quinupristin/dalfopristin (Synercid), ampicillin, erythromycin, clarithromycin, vancomycin, teicoplanin, ciprofloxacin and tetracycline were examined and compared against 526 gram-positive bacteria. The minimal inhibitory concentrations (MICs) for quinupristin/dalfopristin against Staphylococcus aureus, including methicillin-resistant strains, were low (MIC(90) = 0.5 mg/l), and were comparable with those of vancomycin and teicoplanin. This compound was superior to the macrolides and highly active against Streptococcus pneumoniae (both penicillin-sensitive and penicillin-resistant strains), with MIC(90) = 2 mg/l. It was also active against other streptococci, with MIC(90) = 4 mg/l. However, this agent is less active against enterococci (MIC(90) = 32 mg/l). Quinupristin/dalfopristin showed high activity against gram-positive anaerobes, including Clostridium spp., Peptococcus spp. and Peptostreptococcus spp., with MIC(90) < or = 2 mg/l. Quinupristin/dalfopristin was also investigated for its post-antibiotic effect (PAE) and bactericidal kinetics against nine strains of gram-positive organisms, including staphylococci, enterococci and pneumococci. Exponentially growing (log phase) cultures were exposed to quinupristin/dalfopristin at 2 x MIC. Growth kinetics was evaluated using viable counting. The drug was uniformly bactericidal against pneumococci and staphylococci within 2 and 8 h of exposure, respectively. The killing activity against enterococci was weak; there was little or no reduction in bacterial count over 24 h of incubation. PAEs ranging from 2.13 to 3.28 h, 0.92 to 3.02 h and 1.89 to 7.07 h were produced on the tested pneumococci, staphylococci and enterococci, respectively. This study showed that quinupristin/dalfopristin is a promising agent active against gram-positive bacteria. The prolonged PAEs also suggest that the drug could be used intermittently at more widely spaced dosing intervals against gram-positive organisms.

Authors+Show Affiliations

Department of Microbiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, SAR, PR China. lingt@mailserv.med.cuhk.edu.hkNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

11399860

Citation

Ling, T K., et al. "In Vitro Activity and Post-antibiotic Effect of Quinupristin/dalfopristin (Synercid)." Chemotherapy, vol. 47, no. 4, 2001, pp. 243-9.
Ling TK, Fung KS, Cheng AF. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid). Chemotherapy. 2001;47(4):243-9.
Ling, T. K., Fung, K. S., & Cheng, A. F. (2001). In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid). Chemotherapy, 47(4), 243-9.
Ling TK, Fung KS, Cheng AF. In Vitro Activity and Post-antibiotic Effect of Quinupristin/dalfopristin (Synercid). Chemotherapy. 2001 Jul-Aug;47(4):243-9. PubMed PMID: 11399860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid). AU - Ling,T K, AU - Fung,K S, AU - Cheng,A F, PY - 2001/6/16/pubmed PY - 2001/7/20/medline PY - 2001/6/16/entrez SP - 243 EP - 9 JF - Chemotherapy JO - Chemotherapy VL - 47 IS - 4 N2 - The in vitro activities of quinupristin/dalfopristin (Synercid), ampicillin, erythromycin, clarithromycin, vancomycin, teicoplanin, ciprofloxacin and tetracycline were examined and compared against 526 gram-positive bacteria. The minimal inhibitory concentrations (MICs) for quinupristin/dalfopristin against Staphylococcus aureus, including methicillin-resistant strains, were low (MIC(90) = 0.5 mg/l), and were comparable with those of vancomycin and teicoplanin. This compound was superior to the macrolides and highly active against Streptococcus pneumoniae (both penicillin-sensitive and penicillin-resistant strains), with MIC(90) = 2 mg/l. It was also active against other streptococci, with MIC(90) = 4 mg/l. However, this agent is less active against enterococci (MIC(90) = 32 mg/l). Quinupristin/dalfopristin showed high activity against gram-positive anaerobes, including Clostridium spp., Peptococcus spp. and Peptostreptococcus spp., with MIC(90) < or = 2 mg/l. Quinupristin/dalfopristin was also investigated for its post-antibiotic effect (PAE) and bactericidal kinetics against nine strains of gram-positive organisms, including staphylococci, enterococci and pneumococci. Exponentially growing (log phase) cultures were exposed to quinupristin/dalfopristin at 2 x MIC. Growth kinetics was evaluated using viable counting. The drug was uniformly bactericidal against pneumococci and staphylococci within 2 and 8 h of exposure, respectively. The killing activity against enterococci was weak; there was little or no reduction in bacterial count over 24 h of incubation. PAEs ranging from 2.13 to 3.28 h, 0.92 to 3.02 h and 1.89 to 7.07 h were produced on the tested pneumococci, staphylococci and enterococci, respectively. This study showed that quinupristin/dalfopristin is a promising agent active against gram-positive bacteria. The prolonged PAEs also suggest that the drug could be used intermittently at more widely spaced dosing intervals against gram-positive organisms. SN - 0009-3157 UR - https://www.unboundmedicine.com/medline/citation/11399860/In_vitro_activity_and_post_antibiotic_effect_of_quinupristin/dalfopristin__Synercid__ L2 - https://www.karger.com?DOI=10.1159/000048530 DB - PRIME DP - Unbound Medicine ER -